SUN-402 - Evaluation of Psychosocial Comorbidities in Thyroid Eye Disease: US Claims Based Matched Cohort Analysis

Background and Aim
Thyroid eye disease (TED) severely impacts patients’ psychosocial well-being and quality of life. Studies report anxiety and depression prevalence rates in patients with TED ranging from 18% to 70%. This study aimed to quantify the prevalence of psychosocial comorbidities in patients with TED compared with the general population, using comprehensive real-world claims data.

Methods
A retrospective 1:1 matched cohort analysis was conducted using de-identified fully adjudicated claims data from IQVIA PharMetrics® Plus (Q2 2016 to Q3 2024). Adults with TED were identified based on a diagnosis of Graves’ disease and documentation of at least two TED-related ocular symptoms. The index date was the first diagnosis of goiter within the index period (Q1 2017 to Q3 2023). Psychosocial comorbidities diagnosed within 12 months from the index date were assessed, excluding patients with pre-existing psychosocial conditions. A 1:1 propensity score-matched non-TED population was constructed based on age, gender, geographic region, index year, smoking status, payer type, and Charlson Comorbidity Index (CCI).

Results
The TED cohort (n=6,205; median [IQR] age: 53 [42–61] years; 74% female) showed a significantly higher prevalence of psychosocial comorbidities compared with the non-TED population (17.6% vs 13.3%; p< 0.001; OR 1.4, 95% CI: 1.3–1.5). Among the TED cohort, anxiety (54%) and depression (29%) were the most common diagnoses within 12 months from the index date. Despite the substantial burden, psychosocial treatments, including pharmacotherapy (22%) and psychotherapy (3%), were underutilized or underreported among the TED cohort.

Conclusions
Patients with TED face a substantially higher burden of psychosocial comorbidities compared with the general (non-TED) population, yet treatment rates remain low. This highlights a critical unmet need for multidisciplinary care strategies to address the physical and psychosocial challenges faced by patients with TED. Our findings call for targeted interventions to bridge this care gap and improve overall patient outcomes.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*